Experts are rapidly focused on retatrutide, a novel drug from Eli Lilly, as a possible step in weight loss . Different than many existing approaches, retatrutide is a double -action receptor targeting equally GLP-1 and GIP, substances that influence hunger and blood glucose control . Early clinical